List of Excipients in Branded Drug ENTERO VU 24%

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	ACACIA
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	ANHYDROUS CITRIC ACID
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	CARRAGEENAN SODIUM
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	DIMETHICONE 1000
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	DIMETHICONE 350
E-Z-EM Canada Inc	ENTERO VU 24%	barium sulfate	32909-145	METHYLCELLULOSE

Entero VU 24% Excipient Strategy and Commercial Opportunity Analysis

Last updated: September 24, 2026

Entero VU 24% is an oral barium sulfate suspension used as a positive contrast agent for computed tomography of the abdomen and pelvis. Its commercial value depends less on the active ingredient, which is an established inorganic contrast medium, and more on suspension stability, patient tolerability, dose convenience, packaging, and imaging workflow integration. The strongest opportunities are line extensions, ready-to-use packaging, pediatric and low-volume presentations, and differentiated formulations for CT enterography.

What is Entero VU 24% and who markets it?

Entero VU 24% contains barium sulfate at 24% weight/volume. The product is administered orally to opacify the gastrointestinal tract before CT imaging and is not intended for systemic absorption.

Attribute	Entero VU 24%
Active ingredient	Barium sulfate
Strength	24% w/v
Dosage form	Oral suspension
Primary use	CT imaging of the abdomen and pelvis
Administration	Oral
Pharmacologic class	Radiopaque contrast agent
Route of elimination	Fecal
Regulatory pathway	FDA-approved drug product under an NDA
Primary commercial differentiators	Suspension uniformity, palatability, preparation time, packaging, supply reliability

Barium sulfate is chemically and commercially mature. The product’s value proposition is therefore based on delivery performance rather than molecular innovation. The FDA prescribing information identifies excipients used to maintain suspension properties, preserve the product, control pH, and improve administration characteristics.[1]

What excipients are used in Entero VU 24%?

The disclosed excipient system includes sorbitol, xanthan gum, sodium citrate, citric acid, and potassium sorbate. The exact approved formulation and inactive-ingredient listing should be treated as the regulatory reference for any development or substitution program.[1,2]

Excipient	Likely formulation function	Commercial relevance
Sorbitol	Sweetener, humectant, mouthfeel modifier	Influences palatability and gastrointestinal tolerance
Xanthan gum	Suspending and viscosity-modifying agent	Controls sedimentation and redispersibility
Sodium citrate	Buffer and pH-control component	Supports chemical stability and sensory profile
Citric acid	Acidulant and buffer component	Controls pH and may affect taste
Potassium sorbate	Preservative	Supports microbiological stability in a multidose or opened-container format

Why xanthan gum is strategically important

Barium sulfate has a high density and naturally tends to sediment. Xanthan gum increases continuous-phase viscosity and reduces settling during storage. The commercial challenge is balancing three properties:

1. Sedimentation resistance during shelf life.
2. Rapid redispersion after shaking.
3. Sufficiently low viscosity for patient drinking and clinical handling.

A formulation with excessive xanthan gum may remain physically stable but become difficult to pour, drink, or transfer through ancillary equipment. A formulation with insufficient viscosity may require aggressive shaking and produce nonuniform barium concentration during dosing.

Why sorbitol creates both value and risk

Sorbitol can improve sweetness and mouthfeel, but higher exposure may create gastrointestinal discomfort, bloating, or loose stools in susceptible patients. A competing product could seek differentiation through a lower-sorbitol, non-sorbitol, or alternative sweetening system.

Any replacement would require evaluation of:

• Taste and aftertaste.
• Osmolality.
• Gastrointestinal tolerability.
• Microbial preservation.
• Compatibility with xanthan gum.
• Barium sedimentation and redispersion.
• Pediatric acceptability.
• Labeling implications for patients with sugar-intolerance concerns.

What excipient strategy best protects Entero VU 24% performance?

The most defensible strategy is a performance-based formulation platform rather than reliance on a single excipient.

Core formulation targets

Performance attribute	Target commercial outcome
Sedimentation	Minimal hard cake formation during labeled shelf life
Redispersibility	Uniform suspension after routine shaking
Viscosity	Easy oral administration without excessive thickness
Palatability	Reduced refusal, especially in pediatric and high-volume CT protocols
Microbial stability	Reliable shelf life after manufacturing and normal handling
Dose uniformity	Consistent barium delivery across the administered volume
Radiopacity	Adequate bowel visualization at practical dose volumes
Packaging compatibility	No leaching, adsorption, or container interaction

The development program should screen xanthan gum grade, concentration, hydration process, mixing shear, preservative level, buffer ratio, and sorbitol concentration as a linked system. Excipient changes cannot be assessed independently because viscosity, taste, preservation, and sedimentation are interdependent.

Manufacturing process as an IP and quality lever

The most valuable technical know-how may reside in the manufacturing process rather than the ingredient list. Relevant process variables include:

• Order of addition.
• Xanthan gum prehydration.
• Barium sulfate wetting and dispersion.
• Mixing energy and duration.
• Deaeration.
• Hold time before filling.
• Fill-volume accuracy.
• Homogenization or controlled recirculation.
• Container closure performance.

A competitor can use the same excipients and still produce a materially different product if the process creates larger agglomerates, faster settling, air entrapment, or poor redispersion. Process controls can support regulatory consistency and may provide trade-secret protection even where composition claims are difficult to obtain.

What formulations could create new commercial opportunities?

Lower-volume CT enterography formulation

A lower-volume product could reduce patient burden while maintaining diagnostic bowel opacification. This would require higher radiopacity per administered volume or a formulation optimized for targeted intestinal distribution.

The development tradeoff is straightforward: higher concentration may increase density, viscosity, sedimentation pressure, and palatability challenges. A lower-volume product would need strong comparative imaging data rather than relying only on physical characterization.

Pediatric formulation

Pediatric imaging is an attractive segment because administration failure can delay imaging, require repeat procedures, or increase use of sedation. Opportunities include:

• Smaller unit-dose bottles.
• Improved flavor masking.
• Lower viscosity.
• Age-specific dosing aids.
• Reduced volume per dose.
• Clear labeling for caregivers and radiology staff.

Pediatric claims would require age-specific clinical and usability support. The formulation should not rely solely on a sweeter taste because excessive sweetener or osmolality may worsen gastrointestinal tolerance.

Ready-to-drink unit-dose packaging

Ready-to-use packaging can compete on workflow efficiency. Potential formats include:

• 100 mL, 200 mL, and 450 mL bottles.
• Premeasured multi-bottle kits.
• Tamper-evident unit doses.
• Pour-friendly closures.
• Barcoded bottles linked to imaging protocols.
• Packaging designed for administration at the imaging center.

Unit-dose packaging can reduce preparation errors and nursing or technologist time. Its disadvantages are higher packaging cost, greater shipping volume, and possible waste when protocols vary by patient size.

Flavor and sensory line extensions

Flavor differentiation has commercial potential, but taste optimization must account for the chalky, dense mouthfeel of barium suspensions. Candidate approaches include:

• Citrus or fruit profiles.
• Reduced-acid formulations.
• Sweetener combinations.
• Flavor encapsulation.
• Lower residual mouth coating.
• Pediatric and adult flavor variants.

Flavor patents are generally weaker than formulation-performance patents because competitors may design around them. The stronger commercial approach is to link flavor claims with measurable administration outcomes, such as improved completion rate or reduced refusal.

How strong is the patent estate for Entero VU 24%?

Barium sulfate is an old active ingredient, so composition-of-matter exclusivity is not commercially relevant. The primary protection opportunities are narrower and may include:

Protection category	Potential strength
Barium sulfate composition	Very weak or unavailable because of long-established use
Excipient combination	Moderate only if tied to unexpected stability, tolerability, or imaging performance
Suspension process	Moderate to strong as trade secret; patent strength depends on narrow process definition
Packaging	Moderate where packaging solves dosing, sedimentation, or workflow problems
Flavor system	Usually weak unless linked to measurable clinical or operational benefit
Method of use	Limited for conventional abdominal CT; stronger for defined imaging protocols or patient populations
Manufacturing specifications	Strong operational value, but often better protected as confidential know-how

A formulation patent would need more than a list of common excipients. A stronger claim could define a concentration range, viscosity profile, sedimentation rate, redispersion time, particle-size distribution, or preservative system that produces a measurable advantage over existing barium suspensions.

What is the FDA and Orange Book position?

Entero VU 24% is an FDA-approved oral barium sulfate product. The regulatory product is an approved drug, but it is not a biologic and does not present biosimilar exposure. Generic or follow-on competition would arise through drug-product pathways rather than the biosimilar pathway.

Regulatory issue	Assessment
FDA status	Approved oral barium sulfate contrast product
Biosimilar risk	Not applicable
Generic substitution	Possible, subject to product-specific FDA requirements
Active-ingredient exclusivity	Not commercially meaningful
Formulation exclusivity	Potentially relevant only if supported by active patent or regulatory exclusivity
Orange Book relevance	Product-specific patent and exclusivity listings determine formal barriers
Paragraph IV risk	Relevant only if an eligible listed patent remains in force
Method-of-use patents	Potentially relevant but likely narrow for conventional CT use

A Paragraph IV challenge would have commercial significance only if Entero VU 24% had an unexpired, Orange Book-listed patent covering the formulation, use, or other protected feature. For a mature barium sulfate product, the main generic-entry barriers are more likely to be formulation development, manufacturing validation, supply qualification, and clinical workflow adoption than basic active-ingredient rights.

When could a generic or competing product launch?

A competing product could enter through several routes:

1. A therapeutically equivalent or comparable oral barium sulfate suspension.
2. A product with a different excipient system and equivalent imaging purpose.
3. A lower-volume or higher-concentration presentation.
4. A ready-to-use unit-dose package.
5. A hospital-focused product with improved supply and procurement economics.

The fastest route would generally be a conventional suspension using established excipients. The highest-value route would be a differentiated product supported by comparative imaging, palatability, or workflow data.

Key launch risks include:

• Failure to match sedimentation behavior.
• Inadequate redispersion after storage.
• Inconsistent dose concentration.
• Preservative failure.
• Packaging incompatibility.
• Poor patient acceptance.
• Limited radiology-department willingness to change protocols.
• Lack of reimbursement differentiation.
• Hospital conversion costs and formulary inertia.

Which commercial opportunities are most attractive?

Opportunity	Market rationale	Development difficulty	Strategic value
Ready-to-drink unit doses	Reduces preparation and dosing variability	Low to moderate	High
Pediatric flavor and volume optimization	Addresses administration failure	Moderate	High
Lower-volume formulation	Improves patient convenience	High	High
Multi-flavor portfolio	Supports patient preference	Moderate	Moderate
Hospital supply contract product	Competes on reliability and price	Low	Moderate
Protocol-specific CT enterography product	Supports premium positioning	High	High
Preservative-free single-use format	Targets sensitivity and packaging concerns	Moderate	Moderate

The most practical near-term opportunity is a ready-to-use, unit-dose product with improved redispersibility and patient acceptability. The most defensible long-term opportunity is a lower-volume formulation supported by comparative imaging and administration data.

How does Entero VU 24% compare with competing contrast strategies?

Product strategy	Advantages	Limitations
Standard barium suspension	Low cost, established imaging use	High volume, chalky texture, sedimentation
Lower-density oral contrast	Easier administration	May provide weaker positive contrast
Water or neutral contrast	Useful for selected CT protocols	Less radiopaque and protocol-dependent
Iodinated oral contrast	Strong radiopacity	Higher systemic safety and cost considerations
Lower-volume concentrated barium	Better patient convenience	Greater viscosity and sedimentation challenge
Ready-to-use unit dose	Better workflow control	Higher packaging and logistics cost

The commercial position of Entero VU 24% is strongest where positive bowel contrast is required and institutions value a familiar, low-cost product. Its vulnerability is patient burden and the operational inconvenience of handling a dense suspension.

Key Takeaways

• Entero VU 24% is a mature oral barium sulfate suspension whose value is driven by formulation and workflow performance.
• Sorbitol, xanthan gum, citrate buffering, and potassium sorbate form the principal excipient architecture disclosed in product information.
• Xanthan gum concentration and processing conditions are central to sedimentation, redispersion, and dose uniformity.
• The most attractive line extensions are pediatric, lower-volume, flavored, and ready-to-use unit-dose products.
• Basic barium sulfate composition claims are unlikely to provide meaningful exclusivity.
• Stronger protection may come from formulation-performance claims, manufacturing know-how, packaging, and protocol-specific clinical data.
• Biosimilar risk is not applicable.
• Generic-entry risk is driven mainly by formulation execution, regulatory requirements, manufacturing reliability, and radiology workflow adoption.
• A product supported by measurable reductions in administration time, refusal, or repeat imaging would have greater commercial defensibility than a flavor-only reformulation.

FAQs

Can Entero VU 24% be reformulated without changing the active ingredient?

Yes. A reformulation can retain 24% w/v barium sulfate while changing sweeteners, suspending agents, preservatives, buffers, flavor, viscosity, or packaging. The sponsor must demonstrate that the changes do not impair stability, microbial quality, dose uniformity, or diagnostic performance.

Is xanthan gum essential in barium sulfate oral suspensions?

Xanthan gum is not chemically essential, but a suspension requires an effective viscosity-modifying and stabilizing system. Alternative polymers may be evaluated, but they can change mouthfeel, redispersibility, preservation, and sedimentation.

Can a competitor patent a lower-volume barium sulfate formulation?

Potentially, but patentability would depend on novelty, non-obviousness, and adequate technical disclosure. A claim limited to a higher concentration may be weak unless the product delivers an unexpected combination of lower volume, acceptable viscosity, stable suspension, and equivalent imaging quality.

Is Entero VU 24% subject to biosimilar competition?

No. Entero VU 24% is a small-molecule/inorganic drug product, not a biologic. Competition would arise through drug-product approval pathways, not biosimilar applications.

What is the strongest commercial differentiation for a new Entero VU competitor?

The strongest differentiation would combine lower patient volume, fast redispersion, reliable dose uniformity, improved palatability, and ready-to-use packaging. A single flavor change would provide weaker protection and limited switching leverage.

References

1. U.S. Food and Drug Administration. (n.d.). Entero VU 24% barium sulfate suspension: Prescribing information.
2. National Library of Medicine. (n.d.). Entero VU 24%: DailyMed drug label. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.